Comprehensive NGS Colorectal Cancer Panel Test – Accurate Genetic Screening

Description

NGS Colorectal Cancer Panel Test – Comprehensive Genetic Profiling for Precision Oncology

The NGS Colorectal Cancer Panel Test from Lab Tests Dubai is a cutting-edge, next-generation sequencing (NGS) diagnostic tool that analyzes the genetic makeup of colorectal tumors to guide precision treatment, predict drug response, and identify hereditary cancer syndromes like Lynch syndrome.

This advanced panel examines clinically relevant genes linked to both sporadic and inherited forms of colorectal cancer, including:

• ✅ APC, TP53 – Tumor suppressor genes
• ✅ KRAS, NRAS, BRAF – Oncogenes that drive resistance to anti-EGFR therapy
• ✅ PIK3CA – Linked to tumor growth and survival
• ✅ MLH1, MSH2, MSH6, PMS2 – DNA mismatch repair (MMR) genes
• ✅ Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB) – Biomarkers for immunotherapy eligibility

This test is essential for:

• Guiding targeted therapies (e.g., avoiding cetuximab in KRAS-mutant tumors)
• Determining immunotherapy eligibility (via MSI-H/TMB-H status)
• Identifying germline mutations that suggest hereditary cancer syndromes
• Informing family risk assessment and genetic counseling
• Supporting oncologists in making evidence-based treatment decisions

With results in just 10–14 days, Lab Tests Dubai empowers oncologists and patients to move beyond one-size-fits-all chemotherapy and embrace personalized, life-extending cancer care.

Available through partner oncology centers, this test ensures accurate, confidential, and clinically actionable insights—so you can fight cancer with science on your side.

Why You Need This Test

If you or a loved one has been diagnosed with colorectal cancer, this test could reveal the genetic drivers of the tumor—so your oncologist can choose the most effective, least toxic treatment from the start.

You need the NGS Colorectal Cancer Panel if:

• You’ve been diagnosed with colon or rectal cancer at any stage
• Your tumor is being tested for MSI or MMR deficiency
• You’re considering targeted therapy or immunotherapy
• You have a family history of colorectal, endometrial, or other Lynch-related cancers
• You were diagnosed under age 50 (early-onset cancer)
• Your doctor wants to avoid ineffective treatments (e.g., anti-EGFR drugs in KRAS mutants)

This test helps:

• Avoid ineffective chemotherapy based on genetics
• Unlock access to immunotherapy (if MSI-H)
• Identify Lynch syndrome—affecting up to 5% of CRC patients
• Guide surgery and surveillance decisions
• Protect family members through genetic counseling

Precision better outcomes, fewer side effects.

Who Should Consider This Test?

The NGS Colorectal Cancer Panel is recommended for:

✅ Patients Diagnosed with Colorectal Cancer
At diagnosis or recurrence—regardless of stage.

✅ Individuals with Early-Onset CRC (<50 years)
Higher likelihood of hereditary syndromes.

✅ Those with Family History of CRC, Endometrial, or Ovarian Cancer
May indicate Lynch or familial adenomatous polyposis (FAP).

✅ Oncologists & Pathologists
Seeking molecular guidance for treatment planning.

✅ Genetic Counselors
Assessing germline risk for patient and family.

This test transforms tumor biology into actionable intelligence making it indispensable in modern oncology.

What Does the Test Reveal?

The NGS panel analyzes:

• 🔬 Single Nucleotide Variants (SNVs) – e.g., KRAS G12D
• 🔬 Insertions/Deletions (Indels) – gene disruptions
• 🔬 Copy Number Variations (CNVs) – gene amplifications/deletions
• 🔬 Microsatellite Instability (MSI) – predicts immunotherapy response
• 🔬 Tumor Mutational Burden (TMB) – another immunotherapy biomarker
• 🔬 Germline vs. Somatic Mutations – distinguishes inherited vs. tumor-only changes

Key Clinical Insights:

• KRAS/NRAS mutations → resistance to cetuximab/panitumumab
• BRAF V600E mutation → aggressive disease, poor prognosis, potential targeted therapy
• MSI-High (MSI-H) → high response to PD-1 inhibitors (pembrolizumab, nivolumab)
• MMR gene mutations (MLH1, MSH2, etc.) → possible Lynch syndrome

These findings directly impact treatment selection, clinical trial eligibility, and family screening.

What Happens If You Skip Genomic Testing?

Without NGS profiling, patients may:

⚠️ Receive ineffective anti-EGFR therapy (if KRAS/NRAS mutated)
⚠️ Miss immunotherapy options (if MSI-H but not tested)
⚠️ Overlook Lynch syndrome, putting family at risk
⚠️ Undergo unnecessary surgeries or aggressive chemo
⚠️ Experience worse outcomes due to delayed precision care

The good news? Colorectal cancer is increasingly treatable with personalized medicine:

• Targeted drugs (e.g., sotorasib for KRAS G12C)
• Immunotherapy for MSI-H tumors (up to 50% response rate)
• Lifestyle and surveillance plans for Lynch families

Early genomic testing longer, higher-quality survival.

How to Prepare for the Test

To ensure accurate results:

✅ Sample Type:

• Tissue: FFPE block or biopsy (primary or metastatic tumor)
• Blood: For germline testing (to distinguish inherited vs. somatic mutations)

✅ No fasting or special prep required
✅ Provide clinical history (diagnosis, stage, family history)
✅ Your doctor will coordinate sample submission from pathology lab

The lab extracts DNA and performs deep NGS sequencing, followed by bioinformatic analysis and expert interpretation.

Test Overview: Next-Generation Sequencing (NGS) Technology

Report Includes:

• Detected mutations with clinical significance (Tier I–IV)
• FDA/ESMO/NCCN guideline recommendations
• Therapeutic implications (approved drugs, clinical trials)
• Hereditary risk flags (for genetic counseling)

Note: Often used alongside IHC for MMR proteins for full assessment.

Benefits of the NGS Colorectal Cancer Panel

🔹 Guides Targeted Therapy
Avoid ineffective drugs; choose precision medicines.

🔹 Unlocks Immunotherapy
MSI-H status opens doors to PD-1 inhibitors.

🔹 Identifies Lynch Syndrome
Protects entire families through genetic testing.

🔹 Reduces Trial-and-Error Treatment
Start with the right therapy first.

🔹 Supports Clinical Trials
Match patients to novel therapies based on genetics.

If you or a loved one is facing colorectal cancer, the NGS Colorectal Cancer Panel gives you the answers you need in 10–14 days.